Prurigo nodularis (or nodular eczema) is a chronic inflammatory skin disease characterized by the appearance of nodular papules, itching and inflammation. This pathology can occur at any age, but is most often diagnosed in adults. Prurigo nodularis belongs to the group of dermatoses, its etiopathogenesis is not fully understood, but trigger factors that contribute to the manifestation of the disease are known, including genetic, immunological and environmental components. The external manifestations of prurigo nodularis are characteristic and can significantly worsen the patient's quality of life, causing both physical discomfort and emotional suffering.
History of the disease and interesting historical facts
Prurigo nodularis was first described in medical literature in the early 20th century, but cases resembling this disease were encountered much earlier. It is known that in the 19th century, some skin treatment books described various forms of eczema that could resemble prurigo nodularis. An interesting fact is that in some cultures, this disease was perceived as a result of unfavorable changes in the environment and was considered a consequence of failures in a person’s life. During the 20th century, prurigo nodularis became more common and began to be studied from both a dermatological and immunological point of view, which contributed to the identification of the mechanism of its development and more effective treatment methods.
Epidemiology
Prurigo nodularis is widespread and can occur in various population groups. According to statistics, the incidence ranges from 0.1% to 3% depending on the region and climate conditions. In most cases, the disease affects people aged 30 to 50 years, but there are cases at an older age and in children. According to research, prurigo nodularis is more common in women than in men, which may be due to different hormonal levels.
Genetic predisposition to this disease
Although prurigo nodularis is not strictly hereditary, certain genetic factors may still influence its development. Published genetic studies have shown that genes associated with immune system function, such as the HLA (human leukocyte antigen) genes, are involved. Mutations in genes involved in inflammation may contribute to increased sensitivity of the skin to environmental factors, which in turn increases the risk of developing prurigo nodularis.
Risk factors for the development of this disease
There are a number of factors that contribute to the development of nodular prurigo, including:
- History of atopic dermatitis.
- Psycho-emotional stress and chronic tension.
- Contact with allergens and irritants.
- Climate conditions: sharply changing temperatures and high humidity.
- Some infections that contribute to inflammatory processes on the skin.
Patients with prurigo nodularis often have comorbidities such as allergic rhinitis or asthma, indicating a general predisposition to allergic reactions.
Diagnosis of this disease
The main symptoms of nodular prurigo include:
- The appearance of itchy papules, which are often localized on the limbs, back and neck.
- Inflammation of the skin around the nodes, redness and swelling.
- Manifestations in the form of crusts, scales and cracks on the skin.
- Nodular formations that can increase in size and stop in several places.
Laboratory tests for nodular prurigo are usually non-specific but may include a complete blood count to determine levels of inflammatory markers. Radiological examinations are not used because the disease does not affect internal organs, but skin allergy tests may be required to exclude other pathologies. Differential diagnosis includes exclusion of other dermatoses such as psoriasis, contact dermatitis, and insect bites.
Treatment
General treatment of nodular prurigo includes the use of local and systemic therapies.
- Pharmacological treatment: antihistamines to control itching, corticosteroids to reduce inflammation and immunomodulators in severe cases.
- Surgical treatment: In rare cases, intervention is required to remove large nodes.
- Other treatments include phototherapy, which uses ultraviolet light to reduce inflammation in the skin, and steam therapy.
List of medications used to treat this disease
The list of medicines may include:
- Diphenhydramine (antihistamine)
- Prednisolone (corticosteroid).
- Crimophen (immunomodulator)
- Tacrolimus (topical immunomodulator)
- Photosensitizers for phototherapy
Disease monitoring
Control steps for monitoring nodular prurigo include regular visits to a dermatologist to assess the skin condition and monitor the effectiveness of therapy. The prognosis for most patients is favorable if treatment recommendations are followed, but long-term disease may lead to the formation of persistent skin changes, which require additional measures for recovery. Possible complications may include secondary infections and persistent skin manifestations.
Age-related features of the disease
Prurigo nodularis can manifest itself differently depending on the age of the patient. In children, the disease is usually milder and easier to treat. In adolescents and young adults, the disease can be more severe due to hormonal changes, and in older people, it is often accompanied by concomitant diseases and requires an individual approach to treatment.
Questions and Answers
- What are the main symptoms of prurigo nodularis? The main symptoms include itchy papules, skin inflammation, crusting and cracking.
- What causes prurigo nodularis? The cause is unknown, but genetic, immunological and environmental factors are suspected.
- What treatment is recommended for nodular prurigo? Treatment includes antihistamines, corticosteroids, and phototherapy if needed.
- How to manage prurigo nodularis in the long term? Regular visits to a dermatologist and following the prescribed treatment will help control the disease.
- How common is prurigo nodularis? The incidence ranges from 0.1% to 3%, and most often occurs in people aged 30 to 50 years.
